Method of production of drugs: powder for inhalation, dosed 200 mg / dose, 400 mg / dose to 30 or 60 doses per inhaler. Treatment of patients with atopic asthma leads omalizumabom in a significant reduction in Fc?RI - receptors on the surface of mast cells, histamine release from mast cells, isolated in patients anchovies omalizumabom after allergen stimulation are reduced by about 90%, compared with the figures for treatment, levels of Post IgE in serum is reduced in proportion to the dose of h / h after the first injection and are at constant level during the period between the introduction of successive doses. table doses omalizumabu that entered as subcutaneously injected every 4 weeks "and" Dose omalizumabu who entered as subcutaneously injected every 4 weeks, and to determine the number of vials for proper dosage please. The main pharmaco-therapeutic effects: are anchovies monoclonal a / t, which is derived from recombinant DNA molecules that selectively anchovies to human immunoglobulin E (IgE). Side effects of drugs and complications of the use of drugs: oral candidiasis, pharyngitis, and dysfoniya headache single cases of glaucoma, increased intraocular pressure, cataract development, remains a potential possibility of AR (rash, hives, itching and erythema, and swelling of eyelids, face, lips and throat). Indications for use drugs: moderate and severe persistent atopic asthma in adults and children aged 12 years, symptomatic treatment is inhaled corticosteroids are not effective. Contraindications to the use of drugs: hypersensitivity to the drug.
No comments:
Post a Comment